Figure 5.

A proposed model for phytoplankton toxin as a future drug molecule. Toxins involve the identification of screening and optimization to increase the affinity through preliminary assays, high throughput screening, and in vitro screening. After successful screening, the phytoplankton toxin enters secondary assays, counter screening, bioavailability, toxicity, metabolism, etc. Then, screening of the phytoplankton toxin and its structural activity relationship can be performed through structural characterization of the protein–ligand complex. After conformation, it enters into modelling and designing of the toxin. Then, it enters into the chemical synthesis, which is more required for the clinical test. After the successful clinical phase is over, the phytoplankton toxin can be used as a drug.